You gotta love a good proxy fight, especially when you have one of the kings of shareholder activism, Carl Icahn, in the ring. And lately, I've been getting bombarded by emails from representatives of all corners.
Yesterday I wrote about the timing of the back-to-back press releasesout of Amylin Pharmaceuticals. The first one announced a significant sales force cut and the second one heralded the earlier-than-expected filing for FDA approval of the once-a-week diabetes drug Byetta. Eli Lillyand Alkermes are partners with AMLN on the long-acting tummy injection. Tuesday afternoon on CNBC's "Street Signs,"LLY's Chairman and CEO John Lechleiter told David Faber he expects the FDA to take about a year to review the application.